相关实验视频
Updated: Jun 21, 2025

15:48
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
9.6K
上部运动神经元占主导地位的运动神经元疾病呈现为非典型帕金森症:临床病理学研究
Aya Murakami1,2, Shunsuke Koga1,3, Shinsuke Fujioka1,4,5
1Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Brain pathology (Zurich, Switzerland)
|July 11, 2024
概括
上部运动神经元占主导地位的运动神经元疾病 (MND) 可以模仿非典型的帕金森症,如皮质神经元综合征 (CBS) 和渐进性超核性 (PSP) 综合征. 这凸显了在这些疾病的差异诊断中需要考虑MND的必要性.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 临床神经学 临床神经学
背景情况:
- 肌缩侧面硬化症 (ALS) 通常会影响上部和下部运动神经元.
- 一些病例呈现出主要的上部运动神经元 (UMN) 症状,称为UMN主导的ALS或初级侧面硬化症.
- 很少有人报告 UMN 主导的模仿皮质神经综合征 (CBS) 的运动神经元疾病 (MND).
研究的目的:
- 阐明UMN占主导地位的MND患者的临床病理学特征.
- 为了区分UMN占主导地位的MND与病理确认的皮质核退化 (CBD) 和渐进性上核麻 (PSP) 综合征.
主要方法:
- 24名患有UMN占主导地位的MND和TDP-43病理的患者的回顾性审查.
- 分析了10名病理确认的CBD患者和10名病理确认的PSP综合征患者的医疗记录.
- 临床特征的比较,包括对CBS和PSP综合征的适应性和诊断标准的满足.
主要成果:
- 在24名UMN占主导地位的MND患者中,有20名被临床诊断为非典型帕金森症 (11名CBS,8名PSP综合征).
- 只有两个UMN占主导地位的MND患者获得了运动神经元疾病的死前诊断.
- 与CBD患者相比,患有UMN占主导地位的MND患者的CBS不太频繁地表现出厌食症,并且不太可能满足CBS标准. 同样,患有PSP综合征的UMN占主导地位的MND患者相比PSP患者,不太可能满足PSP标准.
结论:
- 在UMN占主导地位的MND可以呈现临床特征重叠的非典型帕金森症疾病.
- 在CBS和PSP综合征的差异诊断中考虑UMN占主导地位的MND,特别是当诊断标准未完全满足时.
- 在UMN占主导地位的MND中,TDP-43的病理确认对于准确的诊断至关重要.
相关概念视频
Parkinson's Disease: Overview
522
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
522
Parkinson's Disease: Treatment
251
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
251
Neural Regulation
39.3K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.3K
Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
Myasthenia Gravis: Diagnostic Tests
753
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
753
Chemical Synapses
8.8K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
8.8K

